1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

Inclusion Criteria: Patients aged over 18-60 Behced Disease fulfilling the International Study Group (ISG) criteria, who have a recent exacerbation of large-vessel vascular disease and/or parenchymal neurologic disease For Neurologic Involvement * Patients experiencing an acute exacerbation of parenchymal neurologic disease involving brainstem and/or diencephalic region. * Exacerbation is defined based on the presence of both of the following: * An acute/subacute neurological syndrome including any of hemiparesis, ataxia, dysarthria,headache within the first month of onset of neurologic manifestations (without any prior high dose steroid treatment) * Compatible cranial MRI lesion involving brainstem and/or diencephalic region For Vascular Disease : Patients experiencing an acute exacerbation of vascular disease within the last month, involving * Large arteries (abdominal aorta, pulmonary arteries, extremity arteries) * Large veins (deep vein thrombosis of extremities, caval vein thrombosis, dural sinus thrombosis) * Compatible radiological findings (spiral CT, MR, or Doppler ultrasonography) Exclusion Criteria: For Neurologic Involvement : * Presence of severe neurological sequelae from any previous attacks rendering the patient dependent on others physically or mentally * Any other neurological cause underlying the picture including ischemic central nervous system lesion on MRI * Any previous treatment with biological agents other than interferon-alpha or any previou…